在基层医疗中招募大规模随机对照临床试验:幽门螺杆菌根除阿司匹林试验(HEAT)
HEAT是一项多中心双盲随机对照试验,旨在探究根除幽门螺杆菌(H. pylori)能否减少消化性溃疡出血住院。招募60岁及以上、每日服用阿司匹林(≤325 mg)至少四个月者,采用电子检索工具、自动邮寄和电子随访从基层医疗招募。共发出188,875封邀请信,30,166人签署知情同意,5,355例H. pylori阳性者被随机分组。
要点
- HEAT从英国1,208家全科诊所招募,共发出188,875封邀请信。
- 30,166例签署知情同意,其中5,355例H. pylori阳性者被随机分组(占知情同意者的17.8%)。
- 随机分组者平均年龄73.1±6.9岁(标准差),72.2%为男性。
核心结论
- HEAT试验方法学表明,在英国临床研究网络(UKCRN)协助下,从基层医疗招募大量患者是可行的,并可应用于其他临床结局研究。
研究设计与样本
- 多中心、双盲、随机对照试验,研究对象为60岁及以上、每日服用阿司匹林(≤325 mg)至少四个月者。
- 根据预试验结果,样本量计算预测需从33,000名志愿者中随机分组6,600例H. pylori阳性者,志愿者从170,000名受邀患者中招募。
- 招募于2012年开始,2017年完成;所有参与者从全科诊所招募,并得到英国临床研究网络(UKCRN)协助。
- H. pylori阳性参与者被随机分配至为期一周的根除治疗组或安慰剂组。
- 主要终点为消化性溃疡出血导致的住院;当发生87例经裁定的事件时试验将结束。
主要发现
- 共发出188,875封邀请信,收到38,771份意向回复;30,166例患者签署知情同意,其中5,355例H. pylori阳性者被随机分组(占知情同意者的17.8%)。
- 随机分组者知情同意时平均年龄为73.1±6.9岁(标准差),72.2%为男性。
- 截至2020年9月17日,随机分组(H. pylori阳性)参与者中有531例死亡,无一例死亡由试验治疗导致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Helicobacter Eradication Aspirin Trial (HEAT) is a multicentre, double blind, randomised controlled trial investigating whether Helicobacter (H.) pylori eradication reduces hospitalisation for peptic ulcer bleeding. Recruited participants were aged 60 and over and taking aspirin (≤325 mg daily) for at least four months prior to consent. Based on results of a pilot study, a sample size calculation predicted 6600 H. pylori-positive randomised participants would be required, from 33,000 volunteers, recruited from 170,000 invited patients. Methodology was therefore designed for recruitment of large numbers of patients from primary care using a novel electronic search tool, automated mail-out and electronic follow-up. Recruitment started in 2012 and completed in 2017. METHODS: All participants were recruited from GP practices, with assistance from the UK Clinical Research Network (UKCRN). H. pylori-positive participants were randomised to one week of eradication treatment or placebo. Recruitment was managed using a bespoke web-based database that communicated directly with a programmed search tool downloaded at participating practices. The primary endpoint is hospitalisation due to peptic ulcer bleeding. The trial will end when 87 adjudicated events have occurred, identified from searches of GP databases, review of secondary care admission data and mortality data, and reported events from randomised participants and GPs. RESULTS: HEAT has recruited participants from 1208 GP practices across the UK. Of the 188,875 invitation letters sent, 38,771 returned expressions of interest. Of these, 30,166 patients were consented to the trial, of whom 5355 H. pylori-positive participants (17.8% of those consented) were randomised. Mean age at consent was 73.1 ± 6.9 (SD) years and 72.2% of participants were male. Of the randomised (H. pylori-positive) participants, 531 have died (as of 17 Sep 2020); none of the deaths was due to trial treatment. CONCLUSION: The HEAT trial methodology has demonstrated that recruitment of large numbers of patients from primary care is attainable, with the assistance of the UKCRN, and could be applied to other clinical outcomes studies. TRIAL REGISTRATION: ClinicalTrials.gov ; registration number NCT01506986 . Registered on 10 Jan 2012.
引用
- Stevenson DJ, Avery AJ, Coupland C, et al. Recruitment to a large scale randomised controlled clinical trial in primary care: the Helicobacter Eradication Aspirin Trial (HEAT). Trials. 2022. PMID: 35164864. doi:10.1186/s13063-022-06054-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。